Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Systemic treatment of advanced non-small cell lung cancer.

Traynor AM, Schiller JH.

Drugs Today (Barc). 2004 Aug;40(8):697-710. Review.

PMID:
15510241
2.

[Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].

Langer F, Helsberg K, Schütte WH, Leschinger MI.

Onkologie. 2005 Mar;28 Suppl 1:1-28. Epub 2005 Mar 30. Review. German.

PMID:
15802886
3.

First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype.

Tiseo M, Bartolotti M, Gelsomino F, Ardizzoni A.

Expert Rev Anticancer Ther. 2009 Apr;9(4):425-35. doi: 10.1586/era.09.3. Review.

PMID:
19374597
4.

Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer.

Rocha Lima CM, Joppert MG.

Oncology (Williston Park). 2002 Sep;16(9 Suppl 9):25-31. Review.

5.

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.

Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Review.

PMID:
27223332
6.

Development of gemcitabine in non-small cell lung cancer: the Italian contribution.

Metro G, Cappuzzo F, Finocchiaro G, Toschi L, Crinò L.

Ann Oncol. 2006 May;17 Suppl 5:v37-46. Review.

PMID:
16807461
7.

Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.

Grossi F, Aita M, Follador A, Defferrari C, Brianti A, Sinaccio G, Belvedere O.

Oncologist. 2007 Apr;12(4):451-64. Review.

8.

Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.

Belani CP.

Oncology (Williston Park). 1997 Aug;11(8 Suppl 8):42-5. Review.

9.

Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.

Chu Q, Vincent M, Logan D, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care..

Lung Cancer. 2005 Dec;50(3):355-74. Epub 2005 Aug 31. Review.

PMID:
16139391
10.

Current treatments for advanced stage non-small cell lung cancer.

Stinchcombe TE, Socinski MA.

Proc Am Thorac Soc. 2009 Apr 15;6(2):233-41. doi: 10.1513/pats.200809-110LC. Review.

PMID:
19349493
11.

Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.

Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, Dickson R, Ramani VS, Proudlove C.

Health Technol Assess. 2010 Oct;14(Suppl. 2):71-9. doi: 10.3310/hta14suppl2/10. Review.

PMID:
21047494
12.

Innovative Clinical Trials: The LUNG-MAP Study.

Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR.

Clin Pharmacol Ther. 2015 May;97(5):488-91. doi: 10.1002/cpt.88. Review.

PMID:
25676724
13.

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.

Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP; meta-analysis of bevacizumab in advanced NSCLC collaborative group..

Ann Oncol. 2013 Jan;24(1):20-30. doi: 10.1093/annonc/mds590. Epub 2012 Nov 23. Review. Erratum in: Ann Oncol. 2013 Apr;24(4):1133.

PMID:
23180113
14.

Chemotherapy for advanced non-small cell lung cancer in the elderly population.

Santos FN, de Castria TB, Cruz MR, Riera R.

Cochrane Database Syst Rev. 2015 Oct 20;(10):CD010463. doi: 10.1002/14651858.CD010463.pub2. Review.

PMID:
26482542
15.

Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.

Yang ZY, Liu L, Mao C, Wu XY, Huang YF, Hu XF, Tang JL.

Cochrane Database Syst Rev. 2014 Nov 17;(11):CD009948. doi: 10.1002/14651858.CD009948.pub2. Review.

PMID:
25400254
16.

WITHDRAWN: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease.

Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, Pignon JP.

Cochrane Database Syst Rev. 2012 Apr 18;(4):CD004569. doi: 10.1002/14651858.CD004569.pub3. Review.

PMID:
22513924
17.

Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease.

Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, Pignon JP.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004569. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD004569.

PMID:
17943820
18.

Chemotherapy for advanced non-small-cell lung cancer: modest progress, many choices.

Shepherd FA.

J Clin Oncol. 2000 Nov 1;18(21 Suppl):35S-8S. Review. No abstract available.

PMID:
11060323
19.
20.

Supplemental Content

Support Center